D
DalCor Pharmaceuticals
Precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits
About DalCor Pharmaceuticals
DalCor Pharmaceuticals is a pioneering startup in the field of precision medicine, specifically targeting cardiovascular diseases. The company's primary product, Dalcetrapib, is currently in the Phase 3 clinical trial stage. The drug aims to reduce both fatal and non-fatal heart attacks (myocardial infarction) in patients who have recently suffered from acute coronary syndrome (ACS) and carry a specific genetic marker (ADCY9 AA genotype).
The company's business model revolves around the development and commercialization of this precision medicine. The target market includes patients with cardiovascular diseases and risk factors such as obesity, diabetes, and hypertension. The company's revenue generation strategy is likely based on the successful completion of clinical trials, regulatory approval, and subsequent sales of the drug.
DalCor has already completed the first interventional precision medicine cardiovascular outcomes trial, dal-GenE (DAL-301). The trial aimed to determine Dalcetrapib's ability to reduce cardiovascular morbidity and mortality in a specific population. The ongoing dal-GenE-2 (DAL-302) trial is a continuation of this work, aiming to further evaluate Dalcetrapib's potential in a larger patient population.
To date, Dalcetrapib has been administered to over 15,000 patients, demonstrating a good safety and tolerability profile. This suggests a promising future for the company, provided the ongoing trials continue to yield positive results.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Montreal, Canada
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 43.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Cardiology and cardiovascular, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Sep 2023 | $80M | $500M | Fonds de solidarité FTQ · CTI Life Sciences · TB Pharma · Invest Quebec | ↗ |
| EARLY VCOther financing | May 2020 | $3.9M | $15M | Undisclosed | — |
Growth signals
Latest recorded traffic for DalCor Pharmaceuticals is 2.4K monthly website visits, up 757.1% over the last three months. DalCor Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sanderling Ventures
Series B and later6 investors entered at this stage
Fonds de solidarité FTQ
CTI Life Sciences- TPTB Pharma
Invest Quebec
French Ministry of Economics and Finance
Andes
Other known investors1 additional known investor
- MIMontreal Heart Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DalCor Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DalCor Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.